$TNGX
Tango Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003734 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $5.716M $6.787M $24.54M
YoY Change -160.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.066M $4.433M $7.097M
YoY Change 4970.63% 6799.61% 1509900.0%
% of Gross Profit
Research & Development $21.63M $21.92M $34.08M
YoY Change 68.94%
% of Gross Profit
Depreciation & Amortization $256.0K $200.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $27.70M $26.36M $41.18M
YoY Change 23634.04% 70.09% 8760751.06%
Operating Profit -$19.57M
YoY Change -26.86%
Interest Expense $196.0K $91.00K $208.0K
YoY Change 267.11% 667.28%
% of Operating Profit
Other Income/Expense, Net -$81.00K $41.00K -$117.0K
YoY Change -189.13%
Pretax Income -$21.87M -$19.53M -$16.55M
YoY Change 34437.27% -27.14% 3520325.53%
Income Tax $177.0K $62.00K $53.00K
% Of Pretax Income
Net Earnings -$22.05M -$19.59M -$4.493M
YoY Change 31313.51% -26.91% -46.46%
Net Earnings / Revenue -385.69% -288.64% -18.31%
Basic Earnings Per Share -$0.28
Diluted Earnings Per Share -$249.8K -$279.2K -$268.7K
COMMON SHARES
Basic Shares Outstanding 87.55M 70.16M
Diluted Shares Outstanding 70.16M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $485.3M $503.8M $582.9K
YoY Change 154.97% 32356.85% 2232.69%
Cash & Equivalents $142.7M $205.0M
Short-Term Investments $342.5M $298.8M
Other Short-Term Assets $5.083M $4.534M $151.4K
YoY Change 2670.03% 6412.5%
Inventory
Prepaid Expenses
Receivables $2.000M $8.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $492.3M $516.3M $734.3K
YoY Change 154.26% 31736.42% 2838.34%
LONG-TERM ASSETS
Property, Plant & Equipment $4.832M $4.706M
YoY Change 26.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $166.8M
YoY Change
Other Assets $19.00K $81.00K
YoY Change -50.0%
Total Long-Term Assets $7.817M $13.80M $166.8M
YoY Change -42.61% -91.73% 433185.79%
TOTAL ASSETS
Total Short-Term Assets $492.3M $516.3M $734.3K
Total Long-Term Assets $7.817M $13.80M $166.8M
Total Assets $500.2M $530.1M $167.5M
YoY Change 141.33% 214.84% 263798.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.226M $3.109M $26.28K
YoY Change 75.23% 60035.4% 5872.73%
Accrued Expenses $11.39M $11.07M $328.4K
YoY Change 10496.33% 9973.71% 2332.59%
Deferred Revenue $26.02M $27.81M
YoY Change -18.62%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $40.69M $41.99M $355.2K
YoY Change -0.55% 36393.7% 811.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $114.7M $5.836M
YoY Change 2294260.0%
Total Long-Term Liabilities $114.7M $0.00 $5.836M
YoY Change 2294260.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.69M $41.99M $355.2K
Total Long-Term Liabilities $114.7M $0.00 $5.836M
Total Liabilities $155.4M $164.7M $6.191M
YoY Change -7.85% 2667.87% 15787.76%
SHAREHOLDERS EQUITY
Retained Earnings -$161.3M -$139.3M
YoY Change 56.48%
Common Stock $88.00K $88.00K
YoY Change 120.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $344.7M $365.4M $54.89M
YoY Change
Total Liabilities & Shareholders Equity $500.2M $530.1M $167.5M
YoY Change 141.33% 214.84% 263798.76%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$22.05M -$19.59M -$4.493M
YoY Change 31313.51% -26.91% -46.46%
Depreciation, Depletion And Amortization $256.0K $200.0K
YoY Change 0.0%
Cash From Operating Activities -$16.90M -$41.86M -$708.0K
YoY Change 6997.51% 46803.46% 2360000.0%
INVESTING ACTIVITIES
Capital Expenditures -$696.0K -$1.141M
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$44.51M -$137.1M $32.51K
YoY Change -17.77%
Cash From Investing Activities -$45.21M -$138.3M $32.51K
YoY Change -17.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -120.0K 357.4M 0.000
YoY Change 112.3% -100.0%
NET CHANGE
Cash From Operating Activities -16.90M -41.86M -708.0K
Cash From Investing Activities -45.21M -138.3M 32.51K
Cash From Financing Activities -120.0K 357.4M 0.000
Net Change In Cash -62.23M 177.3M -675.5K
YoY Change 26031.27% 11510.83%
FREE CASH FLOW
Cash From Operating Activities -$16.90M -$41.86M -$708.0K
Capital Expenditures -$696.0K -$1.141M
Free Cash Flow -$16.21M -$40.72M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001819133
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity File Number
EntityFileNumber
001-39485
dei Entity Registrant Name
EntityRegistrantName
TANGO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1195036
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Binney St.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
320-4900
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TNGX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87546430
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204974000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28381000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
298831000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
161939000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4534000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1312000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
516339000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
193632000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4706000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3823000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6732000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7480000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2279000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2279000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
38000
CY2021Q3 us-gaap Assets
Assets
530137000
CY2020Q4 us-gaap Assets
Assets
207252000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3109000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1841000
CY2021Q3 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9978000
CY2020Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6140000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1092000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
959000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
27807000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31977000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
41986000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40917000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6089000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6925000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
116649000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
120805000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5000
CY2021Q3 us-gaap Liabilities
Liabilities
164724000
CY2020Q4 us-gaap Liabilities
Liabilities
168652000
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
56393261
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87544002
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87544002
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40372133
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40372133
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
88000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
40000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
504625000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
141644000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11530000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6849000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
26356000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
15495000
us-gaap Operating Expenses
OperatingExpenses
67532000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139290000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103101000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
365413000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
38600000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
530137000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207252000
CY2021Q3 us-gaap Revenues
Revenues
6787000
CY2020Q3 us-gaap Revenues
Revenues
-11261000
us-gaap Revenues
Revenues
31326000
us-gaap Revenues
Revenues
-1486000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21923000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12977000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56002000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34928000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4433000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2518000
us-gaap Operating Expenses
OperatingExpenses
41777000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19569000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26756000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36206000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43263000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
91000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-50000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
299000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
37000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-50000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-167000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
41000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-46000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
132000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
155000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19528000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26802000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36074000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43108000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
62000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
115000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19590000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26802000
us-gaap Net Income Loss
NetIncomeLoss
-36189000
us-gaap Net Income Loss
NetIncomeLoss
-43108000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.48
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70160663
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35069988
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53397557
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29176082
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19590000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26802000
us-gaap Net Income Loss
NetIncomeLoss
-36189000
us-gaap Net Income Loss
NetIncomeLoss
-43108000
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-12000
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
15000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-27000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
16000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19602000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26787000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36216000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43092000
CY2020Q4 tngx Stock Holders Equity Before Retroactive Application Of Recapitalization
StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
-97944000
CY2020Q4 tngx Stock Holders Equity Retroactive Application Of Recapitalization
StockHoldersEquityRetroactiveApplicationOfRecapitalization
136544000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
38600000
CY2021Q1 tngx Retroactive Application Of Recapitalization
RetroactiveApplicationOfRecapitalization
29990000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
440000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
950000
CY2021Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
15000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12106000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
57891000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
324000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
3000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1196000
CY2021Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-30000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4493000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
54891000
CY2021Q3 tngx Stock Issued During Period Value Acquisitions And Private Investments
StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments
326501000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
193000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3430000
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-12000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19590000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
365413000
CY2019Q4 tngx Stock Holders Equity Before Retroactive Application Of Recapitalization
StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
-47795000
CY2019Q4 tngx Stock Holders Equity Retroactive Application Of Recapitalization
StockHoldersEquityRetroactiveApplicationOfRecapitalization
55700000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7905000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
3000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
408000
CY2020Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
15000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7914000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
417000
CY2020Q2 tngx Retroactive Application Of Recapitalization
RetroactiveApplicationOfRecapitalization
29761000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
3000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
407000
CY2020Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-14000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8392000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
22191000
CY2020Q3 tngx Retroactive Application Of Recapitalization
RetroactiveApplicationOfRecapitalization
51083000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
3000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
418000
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
15000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26802000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
46909000
us-gaap Net Income Loss
NetIncomeLoss
-36189000
us-gaap Net Income Loss
NetIncomeLoss
-43108000
us-gaap Depreciation
Depreciation
641000
us-gaap Depreciation
Depreciation
527000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
748000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
671000
us-gaap Share Based Compensation
ShareBasedCompensation
5576000
us-gaap Share Based Compensation
ShareBasedCompensation
1233000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-171000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
107000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3222000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-421000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-18000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
867000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
914000
tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
3794000
tngx Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
1802000
tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-703000
tngx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-440000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8326000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
126223000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42625000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
88136000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1141000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
650000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
130890000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16337000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
267976000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
101943000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138227000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86256000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
29990000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
80934000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
957000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11000
tngx Proceeds From Business Combination And Pipe Financing Gross
ProceedsFromBusinessCombinationAndPipeFinancingGross
342113000
tngx Payment Of Business Combination And Pipe Financing Transaction Costs
PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts
15615000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
357445000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80945000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
176593000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
82825000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30660000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25168000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
207253000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
107993000
tngx Cash Paid For Leases
CashPaidForLeases
1372000
tngx Cash Paid For Leases
CashPaidForLeases
1332000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
166534000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
417000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
CY2020Q3 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
5800000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87474239
CY2021Q3 tngx Stock Issued During Period Shares In Exchange For Unvested Restricted Stock Awards And Unexercised Stock Options
StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions
6406197
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55700000
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
CY2020Q3 tngx Weighted Average Recapitalized Common Shares
WeightedAverageRecapitalizedCommonShares
3982482
CY2020Q3 tngx Conversion Weightage Percentage
ConversionWeightagePercentage
1
CY2020Q3 tngx Weighted Average Number Of Share Outstanding Basic And Diluted Adjustments
WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments
3982482
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35069988
CY2021Q3 tngx Merger Recapitalization Exchange Ratio
MergerRecapitalizationExchangeRatio
0.34
tngx Weighted Average Recapitalized Common Shares
WeightedAverageRecapitalizedCommonShares
3799945
tngx Conversion Weightage Percentage
ConversionWeightagePercentage
1
tngx Weighted Average Number Of Share Outstanding Basic And Diluted Adjustments
WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments
3799945
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29176082
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P5Y10M24D
us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
6000000.0
CY2021Q3 tngx Receivable Research Extension Fee
ReceivableResearchExtensionFee
24000000.0
CY2021Q3 tngx Accounts Receivable Current Research Extension Fee
AccountsReceivableCurrentResearchExtensionFee
8000000.0
CY2021Q3 tngx Contractassetresearchextensionfee
Contractassetresearchextensionfee
10000000.0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
298841000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
298831000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
161922000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
161939000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7024000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5507000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2318000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1684000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4706000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3823000
CY2021Q3 us-gaap Depreciation
Depreciation
200000
CY2020Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
500000
CY2017Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
4700000
CY2021Q3 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
0.34
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2556000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2652000
CY2021Q3 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6347000
CY2020Q4 tngx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2695000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1075000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
793000
CY2021Q3 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9978000
CY2020Q4 tngx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6140000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3430000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5576000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1233000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4094544
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.88
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M29D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6625511000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5564341
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.92
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
584561
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
247427
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.37
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
8826897
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M4D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
69725604000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1843814
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M24D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
19120394000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-19590000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-26802000
us-gaap Net Income Loss
NetIncomeLoss
-36189000
us-gaap Net Income Loss
NetIncomeLoss
-43108000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19590000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26802000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36189000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43108000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70160663
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35069988
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53397557
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29176082
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8827110
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3979191
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
62000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
115000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0000950170-21-003734-index-headers.html Edgar Link pending
0000950170-21-003734-index.html Edgar Link pending
0000950170-21-003734.txt Edgar Link pending
0000950170-21-003734-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tngx-20210930.htm Edgar Link pending
tngx-20210930.xsd Edgar Link pending
tngx-20210930_cal.xml Edgar Link unprocessable
tngx-20210930_def.xml Edgar Link unprocessable
tngx-20210930_htm.xml Edgar Link completed
tngx-20210930_lab.xml Edgar Link unprocessable
tngx-20210930_pre.xml Edgar Link unprocessable
tngx-ex31_1.htm Edgar Link pending
tngx-ex31_2.htm Edgar Link pending
tngx-ex32_1.htm Edgar Link pending
tngx-ex32_2.htm Edgar Link pending